key: cord-0751280-nokoywdk
authors: Vikse, Jens; Henry, Brandon Michael
title: Tocilizumab in COVID-19: beware of risk of intestinal perforation
date: 2020-05-07
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106009
sha: 09da1f7c0df0de6af2cd76fbe05ea83fcac3b673
doc_id: 751280
cord_uid: nokoywdk

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Tocilizumab is primarily used for rheumatological conditions, including rheumatoid arthritis and giant cell arteritis. Rheumatologists have extensive experience using tocilizumab; however, this may not be the case for intensivists, infectious disease specialists, and other physicians treating critically ill COVID-19 patients. Therefore, we would like to highlight a rare but feared complication of tocilizumab: intestinal perforation [2] . The mechanism for intestinal perforation in patients receiving tocilizumab is not fully understood, but prior diverticulitis has been noted as a risk factor [2] .

The human host receptor of SARS-CoV-2 is angiotensin-converting enzyme 2 (ACE2), which is highly expressed in the intestines [3] . Intestinal viral replication is likely considering the ACE2 expression, gastrointestinal symptoms and presence of SARS-CoV-2 RNA in fecal samples [4, 5] . Some gastrointestinal symptoms, such as abdominal pain, are associated with increased disease severity [5] .

Furthermore, critically ill COVID-19 patients may have altered hemodynamics, potentially leading to intestinal hypoperfusion that can compromise intestinal mucosal integrity. More studies are required to evaluate whether these variables influence the risk of intestinal perforation with tocilizumab in critical COVID-19 cases; however, clinicians should be aware of the potential for this adverse event. Lastly, as tocilizumab attenuates the acute phase response, intestinal perforation may not necessarily cause significant C-reactive protein (CRP) elevation and may initially go unnoticed in sedated and ventilated patients.

Funding: None

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Gastrointestinal symptoms associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis

Ethical Approval: NA